MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical & Regulatory Advisor

MediciNova, Inc., a clinical‑stage biopharmaceutical company listed on the Nasdaq (NASDAQ: MNOV) and the Tokyo Stock Exchange (Code Number: 4875), announced on 18 November 2025 that they have appointed Christopher D. Breder, MD, PhD as their Clinical and Regulatory Advisor. The company said Dr. Breder will provide strategic guidance for MediciNova’s drug‑development programs and will lead their Scientific Advisory Board once formed. #biotech #drugdevelopment #neuroscience #MediciNova #SlimScan #GrowthStocks #CANSLIM